Here are the DEF 14A proxy statements from Bristol-Myers Squibb Co. (BMY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMY filings page.
Bristol Myers Squibb is asking shareholders at its virtual May 5, 2026 meeting to elect 11 directors, approve an advisory say‑on‑pay vote, adopt a 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as auditor, and consider a proposal for an independent board chair.
The proxy highlights 2025 execution: the Growth Portfolio generated $26.4 billion in sales, up 17% over 2024, with seven products annualizing above $1 billion. The company reports 18 global regulatory approvals, completion of a $10 billion debt paydown target ahead of schedule, and a dividend raised for the 16th consecutive year.
Board materials emphasize strong governance, with 10 of 11 director nominees independent, active board refreshment, majority voting with resignation policies, extensive risk oversight, and integration of sustainability and social impact goals into strategy and executive incentives, including expanded use of AI in R&D and operations.